Online inquiry

IVTScrip™ mRNA-Anti-ALCAM, CX-191(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6522MR)

This product GTTS-WQ6522MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets ALCAM gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001243280.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 214
UniProt ID Q13740
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ALCAM, CX-191(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ6522MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10891MR IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MABp1
GTTS-WQ939MR IVTScrip™ mRNA-Anti-EGFR, ABBV-321(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-321
GTTS-WQ1260MR IVTScrip™ mRNA-Anti-EGFR, ABT-414(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABT-414
GTTS-WQ15477MR IVTScrip™ mRNA-Anti-MAPT, UCB-0107(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA UCB-0107
GTTS-WQ13750MR IVTScrip™ mRNA-Anti-ANGPTL3, REGN 1500(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA REGN 1500
GTTS-WQ4218MR IVTScrip™ mRNA-Anti-Factor IX substitute, BIIB029(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BIIB029
GTTS-WQ6167MR IVTScrip™ mRNA-Anti-IGF1R, CP-751871(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CP-751871
GTTS-WQ12307MR IVTScrip™ mRNA-Anti-CSF2, MT203(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MT203
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW